Featured News

Nivolumab Approved for Another Cancer

by Jay Bitkower on March 7, 2015

On March 4, 2015, the FDA approved the Bristo-Myers Squibb (BMS) immunotherapy drug nivolumab (Opdivo) for use in non-small cell lung cancer (NSCLC) patients for whom other drugs have failed. The approval was based on interim results in a Phase III trial testing nivolumab, at 3 mg/kg, against docetaxel, a chemotherapy drug. Nivolumb was found to have extended overall survival (OS) by three months over docetaxel, giving patients on nivolumab a median OS of 9.2… More →

Exposome

by Jay Bitkower on February 16, 2015

A recent segment on NPR, segment, reported about a study, involving tens of thousands of participants over a 50-year period, by Dr. Barbara Cohn from UC Berkeley looking into the effect of environmental factors on the development of breast cancer in mothers and their children. Dr. Cohn plans to map out what’s called the “exposome” (see exposome), which is a map of the exposure of an individual over his or her lifetime to various environmental and… More →

Rebound and Resistance in Targeted Therapies

by Bryan Lewis on December 24, 2014

John Ebos of Roswell Park Cancer Institute was granted a Career Development Award by the Congressionally Directed Medical Research Programs of the Department of Defense (DoD) to study, using a pre-clinical model, rebound and resistance to targeted therapies in RCC. This two-year grant was funded at $602,996 in Fiscal Year 2013 (the latest award year). This project is designed to answer a number of important questions, in regard to targeted therapy, that have not been… More →

Launching New Website

by Jay Bitkower on December 7, 2014

Today ACKC is launching its new website, updating older material and adding new content, which we will continue to do in the future. Two new features on the Homepage are “News” and “Point of View” essays. News will commence with two articles, one highlighting two studies on the use of sunitinib (Sutent) in the elderly, and a second article featuring Maria Czyzyk-Krzeska from the University of Cincinnati. Maria is one of the two winners of… More →

ACKC’s Advocacy Campaign Pays Off!

by Staff on December 6, 2014

Maria Czyzyk-Krzeska of the University of Cincinnati received a two-year, IDEA grant of $474,562 from the Department of Defense to work on the effects of tobacco smoke on growth of clear cell renal cell carcinoma (ccRCC). Smoking is the major risk factor in getting kidney cancer, but the genetic signaling in RCC that is caused by smoking is little understood. The objective of the study is to determine the genetic mutations and other genetic sequencing… More →